Skip to main content
Suzhou Ribo Life Science Co., Ltd. logo

Suzhou Ribo Life Science Co., Ltd. — Investor Relations & Filings

Ticker · 6938 ISIN · CNE100007DS6 HKEX Manufacturing
Open in API
Filings indexed 45 across all filing types
Latest filing 2026-06-05 Governance Information
Country HK Hong Kong
Listing HKEX 6938

About Suzhou Ribo Life Science Co., Ltd.

https://www.ribolia.com

Suzhou Ribo Life Science Co., Ltd. is a clinical-stage biopharmaceutical company recognized as a global pioneer in the development of oligonucleotide-based therapeutics. The company is dedicated to advancing RNA interference (RNAi) technology, specifically focusing on siRNA therapeutics, to address significant unmet medical needs. Ribo Life has established a proprietary, fully integrated R&D platform that supports the entire lifecycle of oligonucleotide drug development, utilizing key innovations such as specialized siRNA delivery technology and RSC chemical modification technology. The company maintains an extensive siRNA drug pipeline, targeting core therapeutic areas including cardiovascular, metabolic, renal, and liver diseases, with a strong emphasis on chronic disease treatment.

Recent filings

Filing Released Lang Actions
Articles of Association
Governance Information Classification · 92% confidence The document is the company’s Articles of Association, detailing its internal rules, share structure, governance framework, board composition, and meeting procedures. This aligns with the definition of Governance Information (CGR), which covers reports on a company’s internal rules and governance practices.
2026-06-05 English
POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll voting results from the 2025 Annual General Meeting (AGM) of Suzhou Ribo Life Science Co., Ltd., detailing the number of votes for, against, and abstentions on each resolution and noting amendments to the articles of association. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Regulatory Filings Classification · 90% confidence The document is a mandated monthly return (Form FF301) submitted to HKEX detailing movements in share capital, issued shares, treasury shares, and public float confirmations for the month ended 31 May 2026. It does not present full financial statements or earnings data (so it’s not an annual or interim report), nor is it announcing a dividend, merger, or executive changes. It is a routine regulatory compliance filing that does not fit into any specific category other than a general regulatory announcement. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-06-04 English
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL APPLICATION SUBMISSION OF RBD1119 INJECTION FOR TREATMENT OF CORONARY ARTERY DISEASE
Regulatory Filings Classification · 83% confidence The document is a voluntary announcement by the company disclosing R&D progress (submission of a Phase II clinical trial application). It does not present financial results, management changes, or a formal report, nor does it solicit votes or describe legal proceedings. It is a general regulatory announcement, best fitting into the catch-all “Regulatory Filings” category (RNS).
2026-05-28 English
H Share Option Scheme
Governance Information Classification · 80% confidence The document is the full text of the company’s H-Share Option Plan rules (“H股购股权计划”), detailing definitions, eligibility, terms of grant, exercise conditions and governance of the share option scheme. It is not a simple announcement of a report (RPA) nor a financing update, earnings release or management change notice. It is a corporate governance instrument setting out internal rules for equity incentives, thus fitting the Governance Information category (CGR).
2026-05-12 Chinese
H Share Incentive Scheme
Governance Information Classification · 75% confidence The document is the full terms and rules of the company’s H-share Equity Incentive Plan (definitions, grant conditions, vesting schedules, trustee arrangements, etc.). It is not announcing a specific transaction, not a simple notice or Q&A transcript, and it contains no financial statements. Rather, it sets out the internal governance policy and rules for equity awards – a corporate governance document. Therefore, it best fits the Governance Information category.
2026-05-12 Chinese

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.